HIV drug B/F/TAF tested in pregnancy for safety and virus control

NCT ID NCT07666386

ENROLLING_BY_INVITATION Disease control Sponsor: Shi Zou Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at the safety and effectiveness of the HIV medication B/F/TAF in pregnant women who have had their virus under control for at least six months. About 50 women in their first trimester will continue taking the drug through pregnancy and 12 weeks after birth. Researchers will track viral levels, side effects, and health outcomes for both mothers and babies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF)
What this could lead to: If successful, this study could provide real-world evidence that B/F/TAF is a safe and effective option for pregnant women with HIV, helping to maintain viral suppression during pregnancy.
What could go wrong: This is an observational study with only 50 participants, so results may not apply to all pregnant women. It does not test a new treatment, and there is always a risk of side effects or loss of viral control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV

Contacts and locations

Locations

Zhongnan Hospital of Wuhan University

Wuhan, Hubei, 430071, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.